Investment Thesis
Abbott is a 137-year-old diversified healthcare compounder with four resilient segments, anchored by the $7.6B FreeStyle Libre CGM franchise growing at 15-20% CAGR. With Medical Devices at +11.9% ex-FX, 54 consecutive years of dividend growth, $7.4B in FY2025 FCF, and a pending Exact Sciences acquisition adding oncology diagnostics, ABT trades at a 7.9% discount to MedTech sector median P/E — offering ~40% upside to our $135–$140 target. Healthcare's recession-resilient nature and ageing demographic tailwinds underpin a HIGH conviction BUY.
$135–$140
+~40% Upside
12-Month Target
FY2025 Revenue
$44.3B
+7.8% YoY
FY2025 FCF
$7.4B
+16% YoY
Gross Margin
52.6%
+230bps vs FY2023
Adj. EPS FY2025
$5.15
FY2026E: $5.55–$5.80
Dividend Yield
~2.7%
54 yrs consecutive growth
Current Price
~$96
vs $175B Mkt Cap
FY2025A — Revenue by Segment
Medical Devices
$21.2B
48% · +11.9% ex-FX · FASTEST GROWING
Diagnostics
$8.9B
21% · Recovering · BOTTOMING OUT
Nutrition
$8.4B
19% · Stabilizing · RESTRUCTURING
Est. Pharma
$5.6B
12% · +7% (5yr CAGR) · STEADY GROWTH
Macro Tailwinds
3.3%
US CPI Inflation (Mar 2026)
4.31%
US 10-Yr Treasury (Apr 2026)
3.50–3.75%
Fed Funds Rate (On Hold)
1.5B+
People Aged 65+ by 2030
● Defensive sector: Non-cyclical demand for CGM, cardiac devices & diagnostics
● EM tailwind: 61% international revenue · Est. Pharma 7%+ for 5 consecutive years
● Rate reset: WACC 7.86%, Beta 0.88 — multiple re-rating provides additional upside as rates normalise
● Demographics: 573M diabetics globally · 18M CVD deaths annually — structural secular demand
WACC: 7.86% (AlphaSpread) | Beta: 0.88 | Risk-Free Rate: 4.34% (US 10-Yr) | Presented by Deepak Prabhu — Irish Student Managed Fund (ISMF) · Apr 19, 2026
Five-Year Financial Track Record
FY2025 Revenue
$44.3B
FY2026E: ~$47.4B
Operating Income
$8.1B
FY2026E: ~$9.0B
Free Cash Flow
$7.4B
+16% YoY · FY2026E: ~$8.0B
ROIC / ROE
12% / 13%
FY2026E: ~12.5%
Revenue ($B) — FY2021–FY2025
Operating CF vs Free Cash Flow ($B)
Income Statement Summary
| Metric | FY2023 | FY2024 | FY2025 | FY2026E ▲ |
|---|---|---|---|---|
| Revenue ($B) | $40.10 | $41.90 | $44.30 | ~$47.4 |
| Gross Margin | 50.30% | 50.90% | 52.6% ▲ | ~53.5%E |
| Operating Income ($B) | $6.50 | $6.80 | $8.10 | ~$9.0E |
| Adj. EPS | $4.67 | $5.00 | $5.15 | $5.55–$5.80 |
| Free Cash Flow ($B) | ~$5.1 | ~$6.4 | ~$7.4 ▲ | ~$8.0E |
| ROIC / ROE | 12.0% / — | 12.0% / 13.0% | 12.0% / 13.0% | ~12.5%E |
FCF +16% YoY to $7.4B in FY2025 · Gross margin expanded 230bps (50.3%→52.6%) · $5B returned to shareholders · $6.7B buyback remaining · Net Debt/EBITDA: comfortable
Discounted Cash Flow (DCF) Model
| WACC Input | Value | Source |
|---|---|---|
| Risk-Free Rate (Rf) | 4.34% | US 10-Yr Treasury |
| Beta (β) | 0.88 | AlphaSpread |
| Equity Risk Premium | 4.18% | AlphaSpread |
| Cost of Equity (CAPM) | 8.01% | Rf + β × ERP |
| Cost of Debt (post-tax) | 4.35% | 5.16% × (1–15.5%) |
| WACC | 7.86% | AlphaSpread ✓ |
Revenue Growth Assumptions & Scenarios
| Year / Assumption | Bear | Base | Bull |
|---|---|---|---|
| Rev Growth FY2026E | 5.50% | 7.00% | 9.00% |
| Rev Growth FY2027E | 5.50% | 8.00% | 10.00% |
| Rev Growth FY2028–30E | 4.50% | 7.00% | 8.50% |
| Terminal Growth Rate (g) | 2.50% | 3.00% | 3.50% |
| EBIT Margin (2030E) | 18% | 20% | 22% |
| WACC | 8.50% | 7.86% | 7.20% |
| Intrinsic Value / Share | $88 | $118 | $148 |
AlphaSpread DCF base: $90.55 (conservative) · Our base case $118 reflects higher FCF conversion & Exact Sciences upside
Dividend Discount Model (DDM)
| DDM Input | Value |
|---|---|
| Current Annual Dividend (D₀) | $2.52 / share |
| Dividend Growth Rate (g) — Base | 7.0% (3-yr avg: 7.7%) |
| Cost of Equity (Ke) | 8.01% (CAPM) |
| Gordon Growth Formula | P = D₁ / (Ke − g) |
| D₁ (next year dividend) | $2.52 × 1.07 = $2.70 |
| Ke − g (spread) | 8.01% − 7.00% = 1.01% |
DDM Scenario Analysis
| Scenario | g (growth) | DDM Value |
|---|---|---|
| Bull | 7.50% | $337 |
| Base ✓ | 7.00% | $267 |
| Bear | 5.50% | $107 |
Combined Valuation Bridge
DCF Base $118 (50%) + DDM $267 (30%) + Peers $108 (20%) → Haircut for risk → $135–$140 target
$118
DCF Base (50%)
+
$267
DDM Base (30%)
+
$108
Peers (20%)
→
Risk Adj.
Haircut Applied
=
$135–$140
12M Price Target
Investment Scenarios
Bear Case
$105–$110
- Nutrition recovery delayed beyond H2 2026
- CGM competition intensifies sharply
- IRS disputes resolved adversely
- China worsens, macro deterioration
- Exact Sciences integration disappointment
Base Case ✓
$135–$140
- 10% EPS growth delivered per guidance
- 7% organic sales growth as guided
- Multiple expands to sector median
- Buybacks accretive at current price
- Exact Sciences adds incremental revenue
Bull Case
$155–$165
- Exact Sciences beats expectations
- CGM sustains 15%+ growth globally
- Volt PFA captures EP market share
- GLP-1 fears definitively debunked
- Nutrition recovers in H1 (ahead of plan)
Abbott Fwd P/E
17.87x
vs 19.41x sector median
Sector Discount
-7.9%
Below MedTech median P/E
P/S Ratio
3.9x
vs 5-yr avg of 5.7x (−32%)
Wall St Upside
+38%
Consensus $146.96
| Company | Mkt Cap | P/S | P/E (TTM) | EV/EBITDA | EV/EBIT | Fwd P/E | Verdict |
|---|---|---|---|---|---|---|---|
| ★ Abbott (ABT) | $175B | 3.9x | 26.8x | 15.4x | 21.1x | 17.87x ◀ | CHEAP |
| Stryker (SYK) | $133B | 5.3x | 40.9x | 20.8x | 25.2x | ~26x | Premium |
| Boston Sci (BSX) | $94B | 4.7x | 32.3x | 19.2x | 25.7x | ~22x | Premium |
| Medtronic (MDT) | $113B | 3.2x | 24.5x | 13.5x | 19.7x | ~16x | Similar |
| Edwards Life (EW) | $45B | 7.5x | 42.3x | 23.1x | 25.3x | ~27x | Premium |
| Becton Dick (BDX) | $44B | 2.0x | 25.2x | 10.0x | 16.9x | ~14x | Discount |
| Intuit Surg (ISRG) | $163B | 16.2x | 57.1x | 43.2x | 53.1x | ~40x | Very Prem. |
| Sector Median | — | — | — | ~18x | — | 19.41x | BENCHMARK |
EV/EBITDA Comparison — Abbott vs MedTech Peers
Abbott EV/EBITDA 15.4x is cheaper than Stryker (20.8x), BSX (19.2x), Edwards (23.1x) — despite growing Medical Devices at +11.9% ex-FX · P/S of 3.9x is 32% below own 5-year avg of 5.7x · Even bears see upside: Low est. $123.56 (+16%) · High: $177.45 (+67%) · Source: AlphaSpread
Six Material Risks — Identified, Assessed & Mitigated
⚠ CGM Competition (Dexcom / Medtronic)
CGM market growing at 15–20% CAGR — large enough for multiple winners. FreeStyle Libre's cost & scale advantage is structural. Lingo consumer pivot opens a new addressable market. Abbott has a 3-year head start in cost-of-goods efficiency.
⚠ Nutrition Business Weakness
Structural fix underway: price/promotion initiatives Q4 2025. 8+ new products launching FY2026. WIC contract recovery path identified. Management guiding H2 2026 volume recovery. Nutrition is 19% of revenue — not existential to the thesis.
⚠ GLP-1 Drugs Reducing CGM Demand
GLP-1 users still require glucose monitoring. Abbott's FreeDM2 trial confirms CGM value alongside GLP-1. Lingo BENEFITS from GLP-1 users wanting metabolic insight. $40M+ US addressable market growth compensates any penetration shift.
⚠ FX & Tariff Headwinds
~61% international revenue creates FX exposure BUT also diversification. 2026 guidance already includes ~1% FX tailwind. Abbott achieved 150bps operating margin expansion DESPITE tariffs in 2025. AA-/Aa3 fortress balance sheet absorbs shocks.
⚠ Exact Sciences Integration Risk
Oncology diagnostics ($10B+ market) is strategically compelling. Abbott has $8.5B cash + $6.7B buyback capacity. Management has proven M&A execution (St. Jude Medical). Bridge financing secured. Clear synergy roadmap.
⚠ Baby Formula Litigation
$53M verdict (March 2026) is manageable vs. $7.4B FCF. Abbott is vigorously appealing. Insurance covers a significant portion. Market has already partially priced this in — stock near 52-week lows.
Investment Recommendation Summary
Current Price
~$96
NYSE: ABT
12M Price Target
$135–$140
~40% upside
Wall St Consensus
$146.96
+38% from $106
Conviction / Rating
HIGH / BUY
~2.7% dividend yield
Sources: Abbott FY2025 10-K · Q4 2025 Earnings Call · AlphaSpread · Abbott 2024 Sustainability Report · 2026 Proxy · Presented by Deepak Prabhu — Irish Student Managed Fund (ISMF) · 19th April 2026